Generic Definity Availability
DEFINITY (perflutren - injectable;intravenous)
Manufacturer: LANTHEUS MEDCL
Approval date: July 31, 2001
Strength(s): 6.52MG/ML [RLD]
Has a generic version of Definity been approved?
No. There is currently no therapeutically equivalent version of Definity available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Definity. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Low density microspheres and suspensions and their use as contrast agents for computed tomography and in other applications
Issued: June 18, 1996
Inventor(s): Unger; Evan C.
Assignee(s): ImaRx Pharmaceutical Corp.
Substantially homogeneous aqueous suspensions of low density microspheres are presented as contrast media for imaging the gastrointestinal tract and other body cavities using computed tomography. In one embodiment, the low density microspheres are gas-filled. With computed tomography, the contrast media serve to change the relative density of certain areas within the gastrointestinal tract and other body cavities, and improve the overall diagnostic efficacy of this imaging method.Patent expiration dates:
- February 22, 2015✓✓
- February 22, 2015
Method of preparing gas and gaseous precursor-filled microspheres
Issued: December 17, 1996
Inventor(s): Unger; Evan C. & Fritz; Thomas A. & Matsunaga; Terry & Ramaswami; VaradaRajan & Yellowhair; David & Wu; Guanli
Assignee(s): ImaRx Pharmaceutical Corp.
Methods of and apparatus for preparing temperature activated gaseous precursor-filled liposomes are described. Gaseous precursor-filled liposomes prepared by these methods are particularly useful, for example, in ultrasonic imaging applications and in therapeutic drug delivery systems.Patent expiration dates:
- December 17, 2013✓
- December 17, 2013
Methods for diagnostic imaging by regulating the administration rate of a contrast agent
Issued: March 7, 2000
Inventor(s): Unger; Evan C. & Matsunaga; Terry & Fritz; Thomas A. & Ramaswami; Varadarajan
Methods for providing an image of an internal region of a patient. Embodiments of the methods involve administering to the patient a contrast agent which comprises a vesicle composition comprising, in an aqueous carrier, a gas or gaseous precursor and vesicles comprising lipids, proteins or polymers. The patient is scanned using diagnostic imaging, such as ultrasound, to obtain a visible image of the region. The contrast agent is administered to the patient at a rate to substantially eliminate diagnostic artifacts in the image. The methods are particularly useful for diagnosing the presence of any diseased tissue in the patient.Patent expiration dates:
- June 19, 2016✓
- June 19, 2016
- Definity Consumer Information (Wolters Kluwer)
- Definity Advanced Consumer Information (Micromedex)
- Perflutren Consumer Information (Wolters Kluwer)
- Perflutren (lipid microspheres) Consumer Information (Wolters Kluwer)
- Perflutren (protein-type a microspheres) Consumer Information (Wolters Kluwer)
- Perflutren lipid microsphere Intravenous Advanced Consumer Information (Micromedex)
- Perflutren protein type a microsphere Intravenous Advanced Consumer Information (Micromedex)
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|